Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6932-6938
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6932
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6932
Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea
Kyu Keun Kang, Dong Ho Lee, Dong Hyun Oh, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeongi-do 463-707, South Korea
Hyun Chae Jung, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 100-744, South Korea
Author contributions: Kang KK, Lee DH and Oh DH were responsible for conception, design of the study, analysis and interpretation of data, and wrote the manuscript; Yoon H, Shin CM, Park YS, Kim N and Jung HC critically revised the article for important intellectual content; all the authors reviewed and approved the final version to be published.
Correspondence to: Dong Ho Lee, PhD, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeongi-do 463-707, South Korea. dhljohn@yahoo.co.kr
Telephone: +82-31-7877006 Fax: +82-31-7874051
Received: December 12, 2013
Revised: January 8, 2014
Accepted: February 26, 2014
Published online: June 14, 2014
Processing time: 186 Days and 6.4 Hours
Revised: January 8, 2014
Accepted: February 26, 2014
Published online: June 14, 2014
Processing time: 186 Days and 6.4 Hours
Core Tip
Core tip: This study aimed to examine Helicobacter pylori (H. pylori) eradication rates using moxifloxacin-containing triple therapy as second-line treatment. The effectiveness of the failed first-line treatment options was compared. The use of moxifloxacin-containing triple therapy resulted in low eradication rates, and there were no differences in the efficacy between the failed first-line regimens. As a result, we recommend tailored therapy for H. pylori and careful antibiotic selection before second-line treatment in South Korea.